Lung Trans
Research type
Research Study
Full title
Lung Trans: Biomarker Analysis to Predict Response in Lung Cancer
IRAS ID
239879
Contact name
Jennifer Child
Contact email
Sponsor organisation
University College London
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
9 years, 11 months, 23 days
Research summary
Lung Trans is a non-interventional, laboratory study. The study aims to develop a greater understanding of lung cancer outcomes by performing molecular and non-molecular profiling of biological samples to examine biomarkers in patients with lung cancer.
No patients will be recruited into the study directly, nor will they be involved in any clinical or non-clinical activities. The study will utilise biological samples obtained from 1398 patients involved in previous ethically approved lung cancer studies (TACTIC, EudraCT No: 2006-000113-38; TOPICAL, EudraCT number: 2004-000729-31; and ET EudraCT Number: 2007-007639-17), all of which are now closed. All patients entered into these three trials have consented to the use of their samples in future biological studies. Available samples, which include formalin fixed paraffin embedded tissue (FFPE tissue), fine needle aspirates, blood, plasma, DNA, buccal and ascitic fluid, are currently stored in the Cancer Institute at UCL. We will investigate how these biomarkers are associated with clinical outcomes such as progression and death (prognostic factors), and whether they could be used as predictive markers to predict how well patients respond to different treatments.
REC name
West Midlands - Solihull Research Ethics Committee
REC reference
18/WM/0206
Date of REC Opinion
3 Aug 2018
REC opinion
Further Information Favourable Opinion